This article is more than 5 years old. Information may no longer be current.

EyeGate receives notice of allowance for EGP-437

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EyeGate Pharmaceuticals received a notice of allowance from the U.S. Patent and Trademark Office for EGP-437, a dexamethasone phosphate formulation, as a method of treating eye conditions, according to a company press release.

EGP-437 is delivered into the ocular tissues via ocular iontophoresis. In clinical trials, EyeGate is evaluating EGP-437 delivered via the EyeGate II iontophoresis delivery system as a potential noninvasive method of treatment of noninfectious uveitis and macular edema, according to the release.

“By protecting the method of delivering this formulation through iontophoresis, we have substantially more control over this unique and potentially paradigm-shifting therapeutic option,” president and CEO of EyeGate Pharma Stephen From said in the release.